Efficacy and safety of neoadjuvant pyrotinib plus docetaxel/liposomal doxorubicin/cyclophosphamide for HER2-positive breast cancer

被引：0
|
作者：
Chunyu Tian
Minghui Wang
Hancheng Liu
Jianping Liu
Mengze Xu
Lihui Ma
机构：
[1] Affiliated Hospital of Chengde Medical University,Department of Breast Surgery
[2] Chengde Medical University,School of Nursing
来源：
Irish Journal of Medical Science (1971 -) | 2023年 / 192卷 / 3期
关键词：
HER2; breast cancer; Neoadjuvant therapy; Pathological response; Pyrotinib; TAC;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1041 / 1049
页数：8
相关论文
共 50 条
  • [31] Efficacy and Safety of Dual Anti-HER2 Blockade and Docetaxel With or Without Carboplatin as Neoadjuvant Regimen for Treatment of HER2-Positive Breast Cancer
    Lin, Binwei
    Fan, Jinjia
    Liu, Fang
    Wen, Yixue
    Li, Jie
    Gao, Feng
    Zhang, Yu
    Feng, Gang
    Du, Xiaobo
    Chen, Wenzhi
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2023, 22
  • [32] Safety and efficacy of pyrotinib for HER-2-positive breast cancer in the neoadjuvant setting: A systematic review and meta-analysis
    Ma, Qian
    Wei, Bai
    Wang, Bi-Cheng
    Wang, Ganxin
    Zhou, Xuan
    Wang, Yan
    ONCOLOGY LETTERS, 2024, 27 (05)
  • [33] Pyrotinib-Containing Neoadjuvant Therapy in Patients With HER2-Positive Breast Cancer: A Multicenter Retrospective Analysis
    Mao, Xiaoyun
    Lv, Pengwei
    Gong, Yiping
    Wu, Xiujuan
    Tang, Peng
    Wang, Shushu
    Zhang, Dianlong
    You, Wei
    Wang, Ouchen
    Zhou, Jun
    Li, Jingruo
    Jin, Feng
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [34] A Phase II Study of Neoadjuvant PLD/Cyclophosphamide and Sequential nab-Paclitaxel Plus Dual HER2 Blockade in HER2-Positive Breast Cancer
    Yang, Ji-Xin
    Yang, Yu-Qing
    Hu, Wen-Yu
    Yang, Lu
    Wu, Jiang
    Wen, Xin-Xin
    Yu, Jing
    Huang, Mei-Ling
    Xu, Dong-Dong
    Tie, Dan-Chen
    Wang, Lei
    Li, Fan-Fan
    Li, Nan-Lin
    ONCOLOGIST, 2024, 29 (01) : e15 - e24
  • [35] Comparative efficacy and safety of pyrotinib plus trastuzumab versus trastuzumab plus pertuzumab and trastuzumab monotherapy in neoadjuvant treatment of HER2-positive breast cancer: A systematic review and meta-analysis
    Yuan, Ye
    Liu, Xumei
    Xu, Gaifeng
    Zhang, Ji
    Chen, Li
    Long, Xin
    CANCER TREATMENT REVIEWS, 2025, 134
  • [36] Real-World Analysis of the Efficacy and Safety of a Novel Irreversible HER2 Tyrosine Kinase Inhibitor Pyrotinib in Patients with HER2-Positive Metastatic Breast Cancer
    Sun, Ying
    Chen, Beibei
    Li, Jisheng
    Peng, Ling
    Li, Shuguang
    Yu, Xuejun
    Li, Li
    CANCER MANAGEMENT AND RESEARCH, 2021, 13 : 7165 - 7174
  • [37] Pyrotinib-based therapeutic approaches for HER2-positive breast cancer: the time is now
    Qi, Xiaowei
    Shi, Qiyun
    Xuhong, Juncheng
    Zhang, Yi
    Jiang, Jun
    BREAST CANCER RESEARCH, 2023, 25 (01)
  • [38] Neoadjuvant chemotherapy with trastuzumab, docetaxel, and carboplatin administered every 3 weeks for Japanese women with HER2-positive primary breast cancer: efficacy and safety
    Sugitani, Ikuko
    Ueda, Shigeto
    Sakurai, Takashi
    Shigekawa, Takashi
    Hirokawa, Eiko
    Shimada, Hiroko
    Takeuchi, Hideki
    Matsuura, Kazuo
    Misumi, Misono
    Fujiuchi, Nobuko
    Takahashi, Takao
    Hasebe, Takahiro
    Osaki, Akihiko
    Saeki, Toshiaki
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2017, 22 (05) : 880 - 886
  • [39] Pertuzumab in Combination with Trastuzumab and Docetaxel in the Neoadjuvant Treatment for HER2-Positive Breast Cancer
    Vieira, Claudia
    Borges, Andreia
    Pereira, Filipa F.
    Antunes, Pedro
    Redondo, Patricia
    Antunes, Luis
    Lopes, Jose M.
    Goncalves, Francisco R.
    Borges, Marina
    Bento, Maria J.
    JOURNAL OF IMMUNOTHERAPY AND PRECISION ONCOLOGY, 2023, 6 (01) : 1 - 9
  • [40] Multicenter analysis of neoadjuvant docetaxel, carboplatin, and trastuzumab in HER2-positive breast cancer
    Isabel Echavarria
    Mónica Granja
    Coralia Bueno
    Sara Lopez-Tarruella
    Paloma Peinado
    Miguel Sotelo
    Yolanda Jerez
    Fernando Moreno
    Gabriela Torres
    Miriam Lobo
    Ivan Marquez-Rodas
    Maria Del Monte-Millan
    Miguel Martín
    Jose Angel García-Saenz
    Breast Cancer Research and Treatment, 2017, 162 : 181 - 189
12345